279 related articles for article (PubMed ID: 33323457)
1. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
Xie X; Lee J; Liu H; Pearson T; Lu AY; Tripathy D; Devi GR; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2021 Feb; 20(2):296-306. PubMed ID: 33323457
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
3. Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Min DJ; He S; Green JE
Anticancer Res; 2016 Jun; 36(6):2649-57. PubMed ID: 27272773
[TBL] [Abstract][Full Text] [Related]
4. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
Zhu X; Straubinger RM; Jusko WJ
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):477-96. PubMed ID: 26252969
[TBL] [Abstract][Full Text] [Related]
6. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
[TBL] [Abstract][Full Text] [Related]
8. Targeting triple-negative breast cancers with the Smac-mimetic birinapant.
Lalaoui N; Merino D; Giner G; Vaillant F; Chau D; Liu L; Kratina T; Pal B; Whittle JR; Etemadi N; Berthelet J; Gräsel J; Hall C; Ritchie ME; Ernst M; Smyth GK; Vaux DL; Visvader JE; Lindeman GJ; Silke J
Cell Death Differ; 2020 Oct; 27(10):2768-2780. PubMed ID: 32341449
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.
Zhu X; Trueman S; Straubinger RM; Jusko WJ
J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):733-746. PubMed ID: 30069744
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
13. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
15. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
[TBL] [Abstract][Full Text] [Related]
16. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
Crawford N; Salvucci M; Hellwig CT; Lincoln FA; Mooney RE; O'Connor CL; Prehn JH; Longley DB; Rehm M
Cell Death Differ; 2018 Nov; 25(11):1952-1966. PubMed ID: 29500433
[TBL] [Abstract][Full Text] [Related]
17. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
[TBL] [Abstract][Full Text] [Related]
18. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
[TBL] [Abstract][Full Text] [Related]
20. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
